Literature DB >> 9143252

Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis.

M C McGuinness1, J M Powers, W B Bias, B J Schmeckpeper, A H Segal, V C Gowda, S L Wesselingh, J Berger, D E Griffin, K D Smith.   

Abstract

The two most common forms of X-linked adrenoleukodystrophy (X-ALD) are the cerebral forms (CER) with an inflammatory demyelinating reaction that resembles multiple sclerosis, and adrenomyeloneuropathy (AMN) which involves primarily the spinal cord and in which the inflammatory reaction is mild or absent. We found no significant association between the childhood cerebral form (CCER) or AMN and the human leukocyte (HLA) class I and Class II antigens including the class II DR2 haplotypes associated with multiple sclerosis. Inflammatory cytokine (tumor necrosis factor-alpha, interleukin-1 beta, interleukin-4, interleukin-6 and interferon-gamma) gene expression was increased in multiple sclerosis brain lesions, as has been reported previously, but much less so in CER brain lesions. These findings suggest that the pathogenesis of the inflammatory response in X-ALD differs from that in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143252     DOI: 10.1016/s0165-5728(97)00020-9

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

Review 1.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

2.  A mouse model for X-linked adrenoleukodystrophy.

Authors:  J F Lu; A M Lawler; P A Watkins; J M Powers; A B Moser; H W Moser; K D Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 3.  Inflammasomes in the CNS.

Authors:  John G Walsh; Daniel A Muruve; Christopher Power
Journal:  Nat Rev Neurosci       Date:  2014-01-08       Impact factor: 34.870

4.  Anti-ganglioside antibodies bind with enhanced affinity to gangliosides containing very long chain fatty acids.

Authors:  Yumi Tagawa; Wouter Laroy; Leonardo Nimrichter; Susan E Fromholt; Ann B Moser; Hugo W Moser; Ronald L Schnaar
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

Review 5.  New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Authors:  Chih-Chung Lin; Brian T Edelson
Journal:  J Immunol       Date:  2017-06-15       Impact factor: 5.422

6.  Chronic IL-1β-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration.

Authors:  Sarah B Matousek; Simantini Ghosh; Solomon S Shaftel; Stephanos Kyrkanides; John A Olschowka; M Kerry O'Banion
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-16       Impact factor: 4.147

Review 7.  Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS.

Authors:  Tobias D Merson; Michele D Binder; Trevor J Kilpatrick
Journal:  Neuromolecular Med       Date:  2010-03-30       Impact factor: 3.843

8.  Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration.

Authors:  Solomon S Shaftel; Thaddeus J Carlson; John A Olschowka; Stephanos Kyrkanides; Sarah B Matousek; M Kerry O'Banion
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

Review 9.  Experimental models of spontaneous autoimmune disease in the central nervous system.

Authors:  Gurumoorthy Krishnamoorthy; Andreas Holz; Hartmut Wekerle
Journal:  J Mol Med (Berl)       Date:  2007-06-14       Impact factor: 4.599

Review 10.  Positron emission tomography imaging of neuroinflammation.

Authors:  Sujatha Kannan; Bindu Balakrishnan; Otto Muzik; Roberto Romero; Diane Chugani
Journal:  J Child Neurol       Date:  2009-09       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.